Company Profile
Guardant Health Stock Price, News & Catalysts
- Ticker:
- GH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
174.75 USD (-2.02%)
Close
Last updated: October 1, 2026
17.3B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, GH closed down 2.02% at $174.75. No new same-company headline was identified in the current news window.
Company overview
Precision Oncology Diagnostics Company
Guardant Health develops blood-based and tissue-based tests for cancer screening, treatment selection, and disease monitoring. Its platform analyzes cell-free DNA and other molecular signals, supported by large clinical datasets, machine learning, centralized laboratories, and regulatory-grade test development.
Advanced-Cancer Testing
Guardant360 tests profile tumor-derived alterations from blood to guide targeted therapy selection in advanced cancer. FDA-approved companion-diagnostic versions support specific oncology drugs, while broader laboratory-developed offerings help clinicians identify actionable mutations when tissue is unavailable or insufficient.
Molecular Residual Disease and Recurrence Monitoring
Guardant Reveal is designed to detect residual disease and recurrence risk after curative-intent treatment. The test extends the company's role from treatment selection in advanced cancer into longitudinal monitoring of patients with earlier-stage disease.
Cancer Screening
Shield is a blood-based colorectal cancer screening test intended to increase screening participation among average-risk adults. Its commercial model depends on primary-care adoption, guideline inclusion, laboratory scale, reimbursement, and the ability to reach patients who do not complete stool-based or endoscopic screening.
Biopharma and Data Services
Guardant works with pharmaceutical companies on clinical-trial testing, companion diagnostics, biomarker development, and real-world data. These collaborations use the same genomic platform and datasets that support clinical testing, creating a second revenue stream alongside physician-ordered tests.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Guardant Health (GH)?
Guardant Health (GH) most recently closed at 174.75 USD, a -2.02% move versus the previous session.
What is the market cap of Guardant Health (GH)?
Guardant Health currently has a market capitalization of 17.3B USD on BioPharmSignal.
What does Guardant Health do?
Precision Oncology Diagnostics Company Guardant Health develops blood-based and tissue-based tests for cancer screening, treatment selection, and disease monitoring. Its platform analyzes cell-free DNA and other molecular signals, supported by large clinical datasets, machine learning, centralized laboratories, and regulatory-grade test...
On which exchange is GH stock listed?
Guardant Health (GH) is associated with NASDAQ, United States, Biopharma.
What is Precision?
Precision Oncology Diagnostics Company Guardant Health develops blood-based and tissue-based tests for cancer screening, treatment selection, and disease monitoring.
Which conditions is Guardant Health targeting with Precision?
Guardant Health is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
What is Oncology?
Precision Oncology Diagnostics Company Guardant Health develops blood-based and tissue-based tests for cancer screening, treatment selection, and disease monitoring.
What is Diagnostics?
Precision Oncology Diagnostics Company Guardant Health develops blood-based and tissue-based tests for cancer screening, treatment selection, and disease monitoring.